DavidJonMoliternoMD
Cardiology • Lexington, KYInterventional Cardiology
Professor of Internal Medicine
Dr. Moliterno is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
900 S. Limestone, 326A CTW
Lexington, KY 40536Phone+1 859-218-0121Fax+1 859-257-6060
Education & Training
Cleveland Clinic FoundationFellowship, Cardiovascular Disease, 1993 - 1994
University of Texas Southwestern Medical CenterFellowship, Cardiovascular Disease, 1990 - 1993
Vanderbilt University Medical CenterResidency, Internal Medicine, 1987 - 1990
Virginia Commonwealth University School of MedicineClass of 1987
Certifications & Licensure
KY State Medical License 2004 - 2025
OH State Medical License 1993 - 2012
TN State Medical License 1988 - 1994
TX State Medical License 1991 - 1994- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2013
- Whos Who in Medicine and Healthcare Marquis Whos Who
- Join now to see all
Publications & Presentations
PubMed
- 594 citationsTicagrelor with or without Aspirin in High-Risk Patients after PCIRoxana Mehran, Usman Baber, Samin K Sharma, David J. Cohen, Dominick J. Angiolillo
The New England Journal of Medicine. 2019-09-26 - 57 citationsTicagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR.Javier Escaned, Davide Cao, Usman Baber, Johny Nicolas, Samantha Sartori
European Heart Journal. 2021-12-01 - 103 citationsTicagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACSUsman Baber, George Dangas, Dominick J. Angiolillo, David J. Cohen, Samin K. Sharma
European Heart Journal. 2020-10-01
Journal Articles
- CYP2C19 Genotyping to Guide Antiplatelet Therapy After Percutaneous Coronary InterventionsDavid J Moliterno, Susan S Smyth, Ahmed Abdel-Latif, JAMA
- Effects of Genetic Variation in Protease Activated Receptor 4 After an Acute Coronary Syndrome: Analysis from the TRACER TrialPaolo Fortina, David J Moliterno, Robert A Harrington, Kenneth W Mahaffey, ScienceDirect
Authored Content
- CYP2C19 Genotyping to Guide Antiplatelet Therapy After Percutaneous Coronary InterventionsAugust 2020
Press Mentions
Antithrombotic Therapy in High Bleeding Risk Part I: Percutaneous Cardiac InterventionsOctober 14th, 2024- No Downside to Immediate Complete Revascularization in ACS: BIOVASCMarch 6th, 2023
- Immediate Complete Revascularization Is Helpful in ACSMarch 6th, 2023
- Join now to see all
Professional Memberships
- Fellow
- Fellow
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
